Five lupus patients in England are in remission after being treated with a groundbreaking therapy that genetically modifies their own cells, doctors have announced. The treatment, known as CAR T-cell therapy, offers the possibility of a cure for the chronic autoimmune disease.
CAR T-cell therapy works by removing a type of white blood cell called T lymphocytes, which are crucial for hunting out infected cells, and engineering them to target and destroy disease. The modified cells are then infused back into the patient, essentially resetting their immune system.
This NHS trial marks what physicians describe as a medical breakthrough. All five patients achieved remission, though the long-term durability of the results remains under observation.
The implications for lupus patients are significant: current treatments only manage symptoms and often carry severe side effects. A one-time cell therapy could fundamentally change disease management.
Experts caution that larger studies are needed to confirm safety and efficacy across broader patient populations. The therapy's complexity and cost also pose questions about scalability.